Read by QxMD icon Read

Anemia hemodialysis

M Safer, I Zemni, F Ben Abderrazak, M Khelil, C Zoghlami, A Ben Abdelaziz
BACKGROUND: Determining the performance level of hemodialysis facilities, including an evaluation of biological tests, is a prerequisite for quality assessment of these healthcare structures. OBJECTIVE: The purpose of this work was to evaluate the compliance and adequacy of biological tests performed in 2014 in Center-East Tunisia hemodialysis units. METHODS: Data were collected using an analysis grid for 15 biological indicators including 11 process items and four results items used to determine the compliance and adequacy rates respectively...
December 12, 2018: Revue D'épidémiologie et de Santé Publique
Thananda Trakarnvanich, Saowanee Thirathanakul, Nongnaphat Sriphueng, Pathitta Thumrongthongjaroon, Sathit Kurathong, Tanun Ngamvichchukorn
BACKGROUND: Citrate anticoagulation is increasingly favored for preventing extracorporeal circuit clotting during renal replacement therapy. This study tested the effect of citrate compared with acetate on heparin avoidance and other parameters. METHODS: Sixty-one chronic hemodialysis (HD) patients were switched from conventional dialysis fluid (acetate) to citrate dialysis fluid and were treated in 3 phases, each lasting 4 weeks: 50%, 25%, and no heparin. Visual clotting score, erythropoiesis stimulating agent (ESA) dose, and laboratory parameters were measured...
December 13, 2018: Blood Purification
Fulvia Costantinides, Gaetano Castronovo, Erica Vettori, Costanza Frattini, Mary Louise Artero, Lorenzo Bevilacqua, Federico Berton, Vanessa Nicolin, Roberto Di Lenarda
Chronic renal failure is a progressive disease characterized by a gradual destruction of nephrons and a consequent reduction of kidney function. End-stage renal disease (ESRD) necessitates renal replacement therapy as peritoneal dialysis, hemodialysis, or transplantation. Patients affected by ESRD or in hemodialysis are at risk for developing a number of comorbidities including hypertension, anemia, risk of bleeding, susceptibility to infection, medication side effects, and oral manifestations associated with the disease itself and with hemodialysis treatment...
2018: International Journal of Dentistry
Halil İbrahim Erdoğdu, Eray Atalay, Gül Gürsoy, Başol Canbakan, Serkan Aktürk, Canan Yazıcı, Orhan Yücel, Sinan Mersin, Sengül Üçer, Özgür Merhametsiz, Can Öner, Merve Erat
BACKGROUND: In hemodialysis patients Hepatitis B virus (HBV) infection is one of the problems. Because of HBV vaccine response is lower than in the general population, in this study it is aimed to determine the factors that may cause inadequate HBV vaccine response in hemodialysis patients. METHODS: In study, HBsAg, anti-HBs, anti-HBc IgG data belonging to 278 patients were obtained from file and computer records. It was seen that seronegative cases had been given recombinant HBV vaccine...
November 28, 2018: Clinical and Experimental Nephrology
Toru Kawai, Yoshie Kusano, Kyouko Yamada, Chikako Ueda, Atsushi Kawai, Takao Masaki
Recent evidence on maintenance administration of epoetin beta pegol, a continuous erythropoiesis receptor activator (CERA), in dialysis patients shows the clinical benefit of bi-weekly administration (Q2W) in improving hematopoiesis and iron use efficiency. We undertook a single-center observational study of 33 Japanese maintenance dialysis patients, whose anemia had been kept stable through weekly administration (Q1W) of darbepoetin (DA), to evaluate the effectiveness of CERA Q2W switched from DA in maintaining hemoglobin (Hb) levels over a 12-month period...
November 14, 2018: Journal of Artificial Organs: the Official Journal of the Japanese Society for Artificial Organs
Calvin J Meaney, Spinel Karas, Ben Robinson, Jamie Gaesser, Alan Forrest, Wojciech Krzyzanski, Mandip Panesar, Gauri G Rao
Erythropoiesis-stimulating agents (eg, epoetin alfa) are the primary treatment for anemia in patients with end-stage renal disease . Hemoglobin variability in and out of a narrow target range is common and associated with higher morbidity and mortality risk. More robust erythropoiesis-stimulating agent response metrics are needed to define optimal dosing and their association with clinical outcomes. In this cross-sectional, single-center, retrospective study, 49 patients with end-stage renal disease on hemodialysis were followed over 12 months...
November 9, 2018: Journal of Clinical Pharmacology
Takahito Niikura, Yukio Maruyama, Satomi Nakashima, Nanae Matsuo, Yudo Tanno, Ichiro Ohkido, Keitaro Yokoyama, Hiroyasu Yamamoto, Takashi Yokoo
The serum levels of hepcidin generally increase in patients with chronic kidney disease (CKD) due to inflammation or a decline in the glomerular filtration rate. However, the differences in the ferrokinetics among dialysis modalities are unclear. We investigated the relationship between serum levels of hepcidin and ferritin among non-dialyzed CKD (ND), hemodialysis (HD), and peritoneal dialysis (PD) patients. We recruited 285 CKD patients (117 ND, 80 HD, and 88 PD patients) and measured the serum levels of hepcidin-25, ferritin, hemoglobin, iron, transferrin saturation (TSAT), albumin, and high sensitivity C-reactive protein (hs-CRP)...
November 8, 2018: Therapeutic Apheresis and Dialysis
Beena Salman, Mehwish Hussain, Kashif Shafique, Salman Imtiaz, Murtaza Fakhruddin Dhrolia
Chronic kidney disease (CKD) affects health and life of patients. They confront anemia, hypertension, infections and cardiovascular disease. Due to these health issues, they are at risk of repeated hospitalizations. The risk factors which propel them to hospitalize are important to know, and by controlling these factors, we can impede preventable hospitalization. This case-control study included 1050 adult CKD patients, conducted in two tertiary care hospitals of Karachi. Variables included were age, gender, ethnicity, area of residence, marital status, education smoking status, comorbids, blood pressure, type of angioaccess, hemodialysis (HD) status, stage of CKD, activity level, and laboratory parameters...
September 2018: Saudi Journal of Kidney Diseases and Transplantation
Ko-Lin Kuo, Szu-Chun Hung, Wei-Cheng Tseng, Ming-Tsun Tsai, Jia-Sin Liu, Ming-Huang Lin, Chih-Cheng Hsu, Der-Cherng Tarng
Background The Taiwan Health Insurance Bureau has conducted a bundled payment system for hemodialysis reimbursement since 1995. The maximum dose of erythropoiesis-stimulating agents allowed by insurance is capped at 20 000 U of epoetin or 100 μg of darbepoetin alfa per month. Nephrologists have avoided the use of high dosages of erythropoiesis-stimulating agents to achieve a hemoglobin level of 10 to 11 g/dL by iron supplementation. The clinical impact of these policies on patients' outcomes is unknown...
August 7, 2018: Journal of the American Heart Association
Daisuke Sato, Tomohito Gohda, Masao Kihara, Yasuhiko Kanaguchi, Takashi Kobayashi, Satoshi Mano, Yu Sasaki, Nao Nohara, Maki Murakoshi, Junichiro Nakata, Hitoshi Suzuki, Seiji Ueda, Satoshi Horikoshi, Yusuke Suzuki
Some patients with chronic kidney disease (CKD) receiving hemodialysis develop erythropoietin-resistant anemia, possibly due to zinc deficiency. The frequency of zinc deficiency in CKD (stages 1-5 and 5D) and CKD improvement via zinc supplementation are not completely verified. Here 500 CKD patients (Stage 1/2, n=100; Stage 3, n=100; Stage 4, n=100, Stage n=5, 100; Stage 5D, n=100) will be recruited to determine the frequency of serum zinc deficiency at each CKD stage. Patients with serum zinc concentrations <80 μg/dL will be treated with zinc acetate dihydrate (NobelzinR) to evaluate its effects on hypozincemia, taste disturbances, and anemia...
October 2018: Acta Medica Okayama
Hans Benno Leicht, Elke Weinig, Beate Mayer, Johannes Viebahn, Andreas Geier, Monika Rau
BACKGROUND: Drug induced immune hemolytic anemia (DIIHA) is a rare complication and often underdiagnosed. DIIHA is frequently associated with a bad outcome, including organ failure and even death. For the last decades, ceftriaxone has been one of the most common drugs causing DIIHA, and ceftriaxone-induced immune hemolytic anemia (IHA) has especially been reported to cause severe complications and fatal outcomes. CASE PRESENTATION: A 76-year-old male patient was treated with ceftriaxone for cholangitis...
October 25, 2018: BMC Pharmacology & Toxicology
Serife Solmaz Medeni, Sinem Namdaroglu, Tugba Cetintepe, Can Ozlu, Funda Tasli, Zehra Hilal Adibelli, Oktay Bilgir, Erhan Tatar
Atypical hemolytic uremic syndrome is a rare and progressive disease caused by uncontrolled alternative complement activation. Dysregulatıon of the complement activation results in thrombotic microangiopathy and multiorgan damage. A 29-yearold woman who was admitted with complaints of vomiting and headache was detected to have acute renal failure with microangiopathic hemolytic anemia (MAHA). After the diagnosis of atypical hemolytic uremic syndrome (aHUS), she was treated with plasma exchange (PE) and hemodialysis (HD)...
September 5, 2018: Hematology Reports
Tomonari Harada, Masaru Obokata, Koji Kurosawa, Hidemi Sorimachi, Kuniko Yoshida, Hideki Ishida, Kyoko Ito, Tetsuya Ogawa, Yoshitaka Ando, Masahiko Kurabayashi, Kazuaki Negishi
Hemodialysis patients have conditions that increase cardiac output (CO), including arteriovenous fistula, fluid retention, vasodilator use, and anemia. We sought to determine the relationships between these factors and CO and to evaluate the effects of the high-output states on ventricular morphology, function, and myocardial energetics in hemodialysis patients, using noninvasive load-insensitive indices. Cardiovascular function was assessed in hemodialysis patients with high output [ejection fraction ≥ 50%, cardiac index (CI) > 3...
October 16, 2018: International Journal of Cardiovascular Imaging
Hiroyuki Amagai, Kentaro Murakami, Haruhito Sakata, Masaya Uesato, Koichi Hayano, Masayuki Kano, Takeshi Fujishiro, Takeshi Toyozumi, Senba Yoshihide, Kohei Yamamoto, Hideki Hayashi, Hisahiro Matsubara
Introduction Cancer patients undergoing hemodialysis might be under-treated because the pharmacokinetics of anti-cancer drugs in such patients remain unknown and out of concern related to the potential development of severe adverse effects. However, patients with chemosensitive cancer, such as esophageal cancer, should receive chemotherapy at a dose that is sufficient to attain a favorable therapeutic effect. We herein present an interesting case involving an esophageal cancer patient who was successfully treated with subtotal thoracic esophagectomy, and adjuvant full-dose chemotherapy with cisplatin and 5-fluorouracil while concomitantly undergoing hemodialysis...
October 10, 2018: Journal of Oncology Pharmacy Practice
Francesc Maduell, Lara Belmar, Jésica Ugalde, Montserrat Laguno, María Martínez-Rebollar, Raquel Ojeda, Marta Arias, Lida Rodas, Florencia Rossi, Laura-Patricia Llovet, Leonardo Nicolás González, Josep Mallolas, Maria-Carlota Londoño
INTRODUCTION: In the interferon era, the treatment of hepatitis C virus (HCV) infection in patients on haemodialysis (HD) was limited due to the significant number of treatment-related adverse events (AEs). Direct-acting antivirals (DAAs) have demonstrated their efficacy and safety in the treatment of HCV in patients with advanced chronic kidney disease on haemodialysis. The objective of the study was to evaluate the success in eliminating HCV infection from our dialysis unit using DAAs, and to assess the impact of HCV elimination on clinical and analytical outcomes...
October 4, 2018: Gastroenterología y Hepatología
Vassilios Liakopoulos, Stefanos Roumeliotis, Sotirios Zarogiannis, Theodoros Eleftheriadis, Peter R Mertens
Oxidative stress (OS) is the result of prooxidant molecules overwhelming the antioxidant defense mechanisms. Hemodialysis (HD) constitutes a state of elevated inflammation and OS, due to loss of antioxidants during dialysis and activation of white blood cells triggering production of reactive oxygen species. Dialysis vintage, dialysis methods, and type and condition of vascular access, biocompatibility of dialyzer membrane and dialysate, iron administration, and anemia all can play a role in aggravating OS, which in turn has been associated with increased morbidity and mortality...
October 4, 2018: Seminars in Dialysis
Wei Xiong, Fang-Fang He, Ren-Yu You, Jing Xiong, Yu-Mei Wang, Chun Zhang, Xian-Fang Meng, Hua Su
Chronic kidney disease (CKD) is an increasing major public health problem worldwide. The number of CKD patients on hemodialysis is growing rapidly as well. Acupuncture technique is one of the traditional Chinese medicine methods and has been used in a variety of diseases. Nowadays, the clinical application of acupuncture technique for CKD patients has become the focus for its effectiveness and security. In this paper, we will review the therapeutic effects and mechanisms of different acupuncture techniques for CKD patients...
2018: American Journal of Chinese Medicine
James B Wetmore, Suying Li, Heng Yan, Hairong Xu, Yi Peng, Marvin V Sinsakul, Jiannong Liu, David T Gilbertson
Whether and how anemia treatment with erythropoiesis stimulating agents (ESAs) before hemodialysis initiation may be associated with lower mortality after dialysis initiation is unknown. We compared all-cause and cardiovascular mortality in two groups of patients who experienced distinct anemia treatment patterns with ESAs before and after hemodialysis initiation. This retrospective cohort analysis included patients initiating hemodialysis April 1, 2012-June 30, 2013, identified from United States Renal Data System end-stage renal disease (ESRD) and pre-ESRD files...
2018: PloS One
Jalal Azmandian, Mohammad Reza Abbasi, Vahid Pourfarziani, Amir Ahmad Nasiri, Shahrzad Ossareh, Shahrokh Ezzatzadegan Jahromi, Hooshang Sanadgol, Somayeh Amini, Arshia Shahvaroughi Farahani
BACKGROUND: Anemia is one of the most prevalent complications in patients with chronic kidney disease, which is believed to be caused by the insufficient synthesis of erythropoietin by the kidney. This phase III study aimed to compare the efficacy and safety of CinnaPoietin® (epoetin beta, CinnaGen) with Eprex® (epoetin alfa, Janssen Cilag) in the treatment of anemia in ESRD hemodialysis patients. METHODS: In this randomized, active-controlled, double-blind, parallel, and non-inferiority trial, patients were randomized to receive either CinnaPoietin® or Eprex® for a 26-week period...
2018: American Journal of Nephrology
Masaki Hara, Yuya Nakamura, Hiroki Suzuki, Rin Asao, Masayuki Nakamura, Kazumasa Nishida, Sachiyo Kenmotsu, Masahiro Inagaki, Mayumi Tsuji, Yuji Kiuchi, Isao Ohsawa, Yoshikazu Goto, Hiromichi Gotoh
BACKGROUND/AIMS: Hepcidin-25 (HEP-25) and erythroferrone (ERFE) are key regulators of iron homeostasis. Correlations among serum ferritin, ERFE, and HEP-25 levels and improvements in anemia have not been evaluated after administration of ferric citrate hydrate (FCH). METHODS: This retrospective observational study investigated 24 patients on hemodialysis with both anemia (hemoglobin [Hb] < 12 g/dL) and hyperphosphatemia (inorganic phosphorus ≥ 6 mg/dL). The patients who were administered FCH (1,500 mg/day) for 12 consecutive weeks and 12 control patients who were administered a phosphate binder other than FCH were included...
September 21, 2018: Nephrology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"